At relapse , an increase in EDSS score of @ points occurred in @ % of natalizumab and @ % of placebo patients ( P = @ ) ; an increase of @ point occurred in @ % of natalizumab and @ % of placebo patients ( P = @ ) ( mean increase in EDSS at relapse : natalizumab = @ ; placebo = @ ; P = @ ) .